• Something wrong with this record ?

Postavení venetoclaxu v léčbě pacientů s chronickou lymfocytární leukemií
[Role of venetoclax in the treatment of patients with chronic lymphocytic leukemia]

Jana Zuchnická

. 2023 ; 10 (3) : 217-219.

Language Czech Country Czech Republic

Persistent link   https://www.medvik.cz/link/bmc23008257

Immunotherapy is the new hope for longer survival for patients with small cell lung cancer. So far, it has only been given in trials, but 2022 has become a breakthrough year. In comprehensive cancer centers, these patients have a chance of receiving reimbursed treatment with durvalumab (with chemotherapy). Our case report focuses on the appropriateness of patient selection for this treatment, as long-term experience outside clinical trials is still limited.

Several years ago, a major change occurred in the treatment of chronic lymphocytic leukemia. New molecules - B-cell receptor inhibitors and inhibitors of antiapoptotic protein Bcl-2 - have entered common clinical practice. These oral agents are gradually replacing conventional immunochemotherapy. Venetoclax is currently the only approved Bcl-2 protein inhibitor in the Czech Republic. It can be administered in monotherapy in patients after treatment failure with B-cell receptor inhibitors or in combination with anti-CD20 monoclonal antibody in both primary and relapse treatment. A major advantage of venetoclax is the potential to achieve deep remission, including undetectable minimal residual disease.

Role of venetoclax in the treatment of patients with chronic lymphocytic leukemia

Bibliography, etc.

Literatura

000      
00000naa a2200000 a 4500
001      
bmc23008257
003      
CZ-PrNML
005      
20241002132024.0
007      
ta
008      
230621s2023 xr f 000 0|cze||
009      
AR
040    __
$a ABA008 $d ABA008 $e AACR2 $b cze
041    0_
$a cze $b eng
044    __
$a xr
100    1_
$a Zuchnická, Jana $7 xx0227525 $u Klinika hematoonkologie LF OU a FN, Ostrava
245    10
$a Postavení venetoclaxu v léčbě pacientů s chronickou lymfocytární leukemií / $c Jana Zuchnická
246    31
$a Role of venetoclax in the treatment of patients with chronic lymphocytic leukemia
504    __
$a Literatura
520    3_
$a Immunotherapy is the new hope for longer survival for patients with small cell lung cancer. So far, it has only been given in trials, but 2022 has become a breakthrough year. In comprehensive cancer centers, these patients have a chance of receiving reimbursed treatment with durvalumab (with chemotherapy). Our case report focuses on the appropriateness of patient selection for this treatment, as long-term experience outside clinical trials is still limited.
520    9_
$a Several years ago, a major change occurred in the treatment of chronic lymphocytic leukemia. New molecules - B-cell receptor inhibitors and inhibitors of antiapoptotic protein Bcl-2 - have entered common clinical practice. These oral agents are gradually replacing conventional immunochemotherapy. Venetoclax is currently the only approved Bcl-2 protein inhibitor in the Czech Republic. It can be administered in monotherapy in patients after treatment failure with B-cell receptor inhibitors or in combination with anti-CD20 monoclonal antibody in both primary and relapse treatment. A major advantage of venetoclax is the potential to achieve deep remission, including undetectable minimal residual disease.
650    17
$a chronická lymfatická leukemie $x farmakoterapie $x genetika $7 D015451 $2 czmesh
650    07
$a protinádorové látky imunologicky aktivní $7 D000074322 $2 czmesh
650    07
$a geny bcl-1 $x fyziologie $x účinky léků $7 D019940 $2 czmesh
650    07
$a geny bcl-2 $x fyziologie $x účinky léků $7 D019254 $2 czmesh
650    07
$a protokoly protinádorové kombinované chemoterapie $x klasifikace $7 D000971 $2 czmesh
650    07
$a rituximab $x farmakologie $x terapeutické užití $7 D000069283 $2 czmesh
650    07
$a syndrom nádorového rozpadu $7 D015275 $2 czmesh
650    07
$a úhrada zdravotního pojištění $7 D007349 $2 czmesh
650    07
$a senioři $7 D000368 $2 czmesh
650    07
$a lidé $7 D006801 $2 czmesh
653    10
$a venetoclax
773    0_
$t Onkologická revue $x 2464-7195 $g Roč. 10, č. 3 (2023), s. 217-219 $w MED00190287
910    __
$a ABA008 $b B 2787 $c 664 c $y p $z 0
990    __
$a 20230620154911 $b ABA008
991    __
$a 20241002132020 $b ABA008
999    __
$a ok $b bmc $g 1947894 $s 1194503
BAS    __
$a 3
BMC    __
$a 2023 $b 10 $c 3 $d 217-219 $i 2464-7195 $m Onkologická revue $x MED00190287
LZP    __
$c NLK197 $d 20241002 $a NLK 2023-17/dk

Find record

Citation metrics

Archiving options